Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Matinas to present data at ICAAC/ICC
September 2015
by  |  Email the author
EDIT CONNECT

SHARING OPTIONS:

BEDMINSTER, N.J.—Clinical-stage biopharmaceutical company Matinas BioPharma Holdings Inc. has announced that it will share preclinical data on MAT2203 and MAT2501, its two lead anti-infective product candidates, at the American Society for Microbiology’s Interscience Conference of Antimicrobial Agents and Chemotherapy and the International Society of Chemotherapy’s International Congress of Chemotherapy and Infection this September. MAT2203 is an oral broad-spectrum fungicidal agent and is expected to begin Phase 2a clinical studies for the treatment of mucocutaneous fungal infections in collaboration with the National Institutes of Health/National Institute of Allergy and Infectious Disease this year. MAT2501 is a gram-negative aminoglycoside antibiotic delivered in Matinas’ proprietary lipid-crystal nano-particle cochleate formulation, and the company expects to file an IND application for MAT2501 in 2015.
 
Code:

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.